February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.
Tag: aduhelm
Aduhelm for the Treatment of Mild Alzheimer’s disease: Controversies and Policies
This article will provide an overview of the controversial drug Aduhelm (generic name aducanumab) that was approved by the Food and Drug Administration (FDA) as a treatment for Alzheimer’s disease for patients with mild cognitive impairment due to Alzheimer’s.
Read More »NCHR Testimony by Dr. Diana Zuckerman about AMX0035 for ALS at FDA Advisory Committee
March 30, 2022. ALS is a devastating disease and all of us want better treatments to be available as soon as possible. But NCHR agrees with FDA that “The secondary endpoint results are not compelling or supportive of the primary endpoint.”
Read More »FDA advisers to discuss ALS drug at Wednesday meeting
Politico, March 29, 2022. On March 30, FDA holds a highly anticipated advisory committee on neurological drugs to discuss a drug from Amylyx that aims to treat amyotrophic lateral sclerosis (ALS). Dr. Diana Zuckerman told Politico: “Did the FDA schedule an advisory committee meeting to placate patient advocates and other political pressure in the hope that the advisory committee would vote against it? Or is the FDA really considering approving it?”
Read More »What You Need to Know About Alzheimer’s Disease and Other Dementias
Alzheimer’s Disease is one of the leading causes of death for Americans ages 65 and older. It is the most common cause of dementia (as much as 60-80% of dementia cases are caused by Alzheimer’s Disease), and 11% of Americans ages 65 and older are estimated to have dementia caused by Alzheimer’s Disease
Read More »